Published Date: 02 Mar 2023
Researchers from the Barts Cancer Institute and the Francis Crick Institute at Queen Mary University of London have discovered why patients with rare blood cancers suffer from the development of poor red blood cells and...
Read Full NewsThe U.S. Department of Justice said on Thursday it would immediately loosen restrictions on some marijuana products and move quickly to reclassify the drug as less...
Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.
Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.
1.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
2.
AI is useful in low-resource areas for triaging breast masses.
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Alkem introduces cetuximab under the trade name Cetuxa in India.
5.
African American men see biggest survival gain from healthier lifestyles post prostate cancer diagnosis
1.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
2.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
3.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
4.
Targeting Oncology: Expanding Combinatorial Strategies by 2025
5.
Case Study: Personalized Medicine Based on Genetic Profiling in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
2.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation